CDNA

Caredx

Stock NASDAQ – Stock Market Prices, News & Analysis

Caredx Inc provides specialized diagnostic solutions, primarily tests for the monitoring of patients who have undergone organ transplantation.

$ 17.15
1.00 %

Caredx

$ 17.15
1.00 %
CDNA

Caredx Inc provides specialized diagnostic solutions, primarily tests for the monitoring of patients who have undergone organ transplantation.

Price history of Caredx
Price history of Caredx

Performance & Momentum

6 Months 34.11 %
1 Year 5.44 %
3 Years 68.61 %
5 Years 73.51 %
Momentum
79

Strategic Analysis

Caredx • 2026

CareDx Inc positions itself as a specialized player in diagnostic solutions for monitoring transplant patients, capitalizing on a high-value niche segment within the medical field. Its model relies on innovative tests that address a specific clinical need, thus providing strong differentiation in the medical technology sector.

Strengths
  • Specialization in a high-tech segment with few direct competitors
  • Portfolio of diagnostics focused on a patient population with high medical needs
  • Strong presence in the rapidly growing medical technology sector in the United States
Weaknesses
  • Significant historical volatility impacting retail investor confidence
  • Strong dependence on the U.S. market, limiting geographical diversification
Momentum

The current momentum reflects a mixed dynamic with a strong recovery expected in the medium term but a negative annual performance, suggesting a stabilization context following periods of adjustment. This trajectory indicates a potential positioning to watch for a sustainable turnaround, particularly due to the lack of recent major news.

Analysis performed 1 week ago

Similar stocks to Caredx

Was this page helpful?

Your feedback helps us improve our research.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases
Anantys Invest on iPhone